Dr prIME Presents: Combinations Are Key, Optimizing Targeted Treatment for <em>BRAF</em>-Mutated Melanoma - priME Oncology
Dr prIME Presents
Dr prIME Presents

Dr prIME Presents: Combinations Are Key, Optimizing Targeted Treatment for BRAF-Mutated Melanoma

Not a member of My prIME? Join now for instant access.

Dr prIME Presents: Combinations Are Key, Optimizing Targeted Treatment for BRAF-Mutated Melanoma

View Activity

Activity Overview

This CME-certified Dr prIME Presents activity combines media types to create an informative, engaging educational experience utilizing animation and motion graphics in addition to video and text. The clinical scenario includes decisions for treatment options and patient management, with faculty providing commentary and insight. The case focuses on a patient with newly diagnosed BRAF-positive metastatic melanoma and assessment of the options given the patient and tumor characteristics, then continues into clinical management of the patient. The activity also includes a video that can be utilized as a patient tool to explain BRAF-targeted therapy and the importance of both discussing potential adverse events with the healthcare team and taking the medicine on a regular basis.


  • Clinical CaseTreatment Choice
  • Adverse Event Management
  • Future Directions
  • Summary and Patient Video


  • Jeffrey S. Weber, MD, PhDLaura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York, United States


  • Sanjiv Agarwala, MDSt Luke’s University Hospital and Temple University
    Easton, Pennsylvania, United States
  • Jeffrey Sosman, MDVanderbilt-Ingram Cancer Center
    Nashville, Tennessee, United States

Target Audience

This activity is specifically designed for medical oncologists and other healthcare professionals who manage and treat patients with melanoma.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Identify best practices for the treatment of BRAF-mutated melanoma, including strategies to prevent or overcome resistance to single-agent BRAF inhibitor therapy
  • Assess recent clinical data supporting emerging targeted agents and combinations of currently approved therapies for unresectable and metastatic melanoma
  • Identify the most common adverse events in BRAF inhibitors
View Activity


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This educational activity is supported by grants from Genentech and Novartis Oncology.

Activity Date

April 1, 2016

April 1, 2017